Lymphocyte antigens

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Targets
Other protein targets
Lymphocyte antigens

Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).

Overview

Show »« Hide

This page is under development, please check back soon.

Targets

3306

CD205 (lymphocyte antigen 75) Show summary »« Hide summary

Target Id

3306

Nomenclature

lymphocyte antigen 75

Common abbreviation

CD205

Previous and unofficial names

CD205 | DEC-205 | LY75

Genes

LY75 (Hs), Ly75 (Mm), Ly75 (Rn)

Ensembl ID

ENSG00000054219 (Hs), ENSMUSG00000026980 (Mm), ENSRNOG00000007012 (Rn)

UniProtKB AC

O60449 (Hs), Q60767 (Mm)

Antibodies

OBT076 (Binding) [3]

Comment

Lymphocyte antigen 75 (CD205) is a type I transmembrane glycoprotein that is classified as a C-type lectin receptor. The protein is differentially expressed in solid malignancies from various histotypes, and by hematological cancer cells. In addition to endocytosis actions, CD205 also appears to have functions in the immune clearance of apoptotic and necrotic cells. CD205 rapidy internalises bound antigens, so makes an ideal target for selective delivery of cytotoxic agents to tumour cells (via an ADC for example). CD205 is an active target for oncology drug development [1-3].

MD-2 (lymphocyte antigen 96) Show summary »« Hide summary More detailed page go icon to follow link

Target Id

2890

Nomenclature

lymphocyte antigen 96

Common abbreviation

MD-2

Previous and unofficial names

LPS co-receptor MD-2 | myeloid differentiation factor-2 | ESOP-1

Genes

LY96 (Hs), Ly96 (Mm), Ly96 (Rn)

Ensembl ID

ENSG00000154589 (Hs), ENSMUSG00000025779 (Mm), ENSRNOG00000067966 (Rn)

UniProtKB AC

Q9Y6Y9 (Hs), Q9JHF9 (Mm)

Selective inhibitors

L6H21 pK_d 4.5 [4]

References

Show »« Hide

1. Ackroyd JE. (2014) Ly75 as cancer therapeutic and diagnostic target. Patent number: WO2014072700A1. Assignee: Oxford Biotherapeutics Ltd. Priority date: 11/06/2013. Publication date: 15/05/2014.

2. Gaudio E, Tarantelli C, Spriano F, Guidetti F, Sartori G, Bordone R, Arribas AJ, Cascione L, Bigioni M, Merlino G et al.. (2020) Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models. Haematologica, 105 (11): 2584-2591. [PMID:33131247]

3. Merlino G, Fiascarelli A, Bigioni M, Bressan A, Carrisi C, Bellarosa D, Salerno M, Bugianesi R, Manno R, Bernadó Morales C et al.. (2019) MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors. Mol Cancer Ther, 18 (9): 1533-1543. [PMID:31227646]

4. Wang Y, Shan X, Chen G, Jiang L, Wang Z, Fang Q, Liu X, Wang J, Zhang Y, Wu W et al.. (2015) MD-2 as the target of a novel small molecule, L6H21, in the attenuation of LPS-induced inflammatory response and sepsis. Br J Pharmacol, 172 (17): 4391-405. [PMID:26076332]

How to cite this family page

Database page citation:

Lymphocyte antigens. Accessed on 31/03/2026. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=924.

Concise Guide to PHARMACOLOGY citation:

Alexander SPH, Gibb AJ, Kelly E, Mathie AA, Peach CJ, Veale EL, Cidlowski JA, Davenport AP, Fabbro D, Spedding M, Striessnig J, Armstrong JF, Buneman OP, Faccenda E, Harding SD, Southan C, Davies JA et al. (2025) The Concise Guide to PHARMACOLOGY 2025/26: Introduction and Other Protein Targets. Br J Pharmacol. 182: S1-S23.